Orphan market exclusivity in the EU: ten years, the exceptions, and what the reform changes

A clock of its own

Since 2000 the EU has rewarded medicines for rare conditions with market exclusivity: for ten years from authorisation, the EU and the member states will not accept or grant an application for a similar medicinal product for the same therapeutic indication. It is not a patent and it is not data protection. It stops the regulator, not the competitor; it covers the indication, not the molecule; and it runs on its own calendar.

To qualify, a product must first be designated orphan: the condition affects no more than five in ten thousand people in the EU (or the product would not be developed without incentives), and there is no satisfactory treatment, or the product is of significant benefit over what exists. Designation must still hold at the time of authorisation.

What “similar” and “same indication” mean

A similar product is one with the same active substance, or one whose principal molecular structural features are the same and which acts by the same mechanism. A generic or a biosimilar of the orphan product is similar by definition; so, often, is a competitor’s closely related molecule, which is what makes the exclusivity valuable. A different molecule for the same disease is not blocked.

The exclusivity attaches to the orphan indication. If the same active substance is also authorised for a common disease (the orphan product is one indication among several), a generic can be authorised for the non-orphan indications with the orphan one carved out of its label, in the same way a patented indication is carved out.

The ten years can be less, or more

Cut to six. At the end of the fifth year a member state can ask for a review; if the product no longer meets the orphan criteria, in particular because it has become sufficiently profitable that the incentive is no longer justified, the exclusivity is reduced to six years. The mechanism exists and has rarely been used.

Extended to twelve. An orphan product with a completed, agreed paediatric investigation plan gets two more years of market exclusivity, instead of the six-month SPC extension that other products receive.

Set aside. A similar product can be authorised during the exclusivity if the orphan holder consents, if the holder cannot supply enough of the product, or if the second product is clinically superior (safer, more effective, or otherwise a major contribution to care). “Clinically superior” has been argued often and granted rarely.

How it interacts with the other clocks

Orphan exclusivity, data protection (eight years), market protection (two, plus one), the patents and the SPC all run at once and independently. For most orphan products the orphan period ends before the SPC, so it adds nothing to the exclusivity date; where a product’s patents are weak or expired, or the product was authorised long after filing, the orphan period can be the last clock standing, and it is the one that a competitor cannot litigate away. A revocation of the patent does nothing to it.

What the reform changes

The EU pharmaceutical package, adopted by the Council in September 2026 and awaiting Parliament’s vote, replaces the flat ten years with tiers for products whose application is filed after it applies (expected late 2028): nine years as the baseline, eleven for “breakthrough” orphan products (a condition with no existing treatment in the EU and a clinically relevant reduction in morbidity or mortality), and a shorter period for products authorised on bibliographic data (reported as four years; to be confirmed from the adopted text). One further year is available for supply in all member states and one for each new orphan indication, capped at two extensions in all. The five-year review that could cut exclusivity to six years is abolished, and generics and biosimilars may file, and be assessed, during the last two years of the exclusivity so that they can launch the day it ends. Products authorised, or filed, before the new rules apply keep today’s ten years.

What it means, by role

For a generics or biosimilar planner. Check the orphan exclusivity date alongside the SPC date; for products where it falls later, it is the launch date, and the register of orphan designations (the EMA’s) is the source. A carve-out strategy for non-orphan indications is available where the molecule has them.

For a parallel trader. Orphan exclusivity does not restrict trade in the originator’s own product; it restricts competitors. Its practical effect is to keep the single-source price in place for longer, which keeps the differential between countries alive.

For a buyer. An orphan product with expired patents is not open to competition until the exclusivity date; procurement built on patent expiry alone will be early by years for some products.

MPA Search records orphan status and exclusivity dates with the patent and SPC position so that the last clock is the one that shows.